Incidencia de hiponotremia secundaria al uso de inhibidores selectivos de la recaptación de serotonina en depresión mayor en pacientes hospitalizados en el hospital Teodoro Maldonado Carbo de Guayaquil entre agosto a diciembre del 2017.

Abstract

SSRIs (selective serotonin reuptake inhibitors) currently represent the most appropriate antidepressant treatment to manage depressive symptomatology. Hyponatremia is one of the possible adverse effects of SSRI use; between 0.5 and 32% of patients who consume these drugs for more than 3 months as the main treatment for major depression may experience a hyponatremic state. In this prospective study for a period of 6 months (August to December 2017), the main laboratory data reflecting the natriotic status of 113 patients hospitalized at the Hospital Teodoro Maldonado Carbo of Guayaquil who met the inclusion and exclusion criteria, to which the levels of natremia were assessed at the time of hospital admission.